| アブストラクト | OBJECTIVE: To assess the impact of lipid-lowering drugs (LLDs) and antihypertensive drugs on the risk of aortic diseases. METHODS: Mendelian randomization was utilized to analyse data from 500 000 participants in the UK Biobank to evaluate the effects of statins, PCSK9 inhibitors (PCSK9i), beta-blockers, and calcium channel blockers on the risks of thoracic aortic aneurysm, abdominal aortic aneurysm, and aortic dissection (AD) using genetic variants as proxies. Real-world pharmacovigilance data from the FAERS (FDA Adverse Event Reporting System) database were used. RESULTS: PCSK9i and statins significantly reduced the risks of aortic aneurysms and AD, respectively. Furthermore, the two LLDs reduced the risk of aortic diseases through certain metabolites. Meanwhile, real-world pharmacovigilance reports also indicated a low incidence of aortic diseases with PCSK9i and statin treatment. CONCLUSION: LLDs, particularly statins and PCSK9i, significantly protect against aortic diseases, providing a scientific basis for preventing and treating aortic diseases. |
|---|
| ジャーナル名 | European heart journal. Cardiovascular pharmacotherapy |
|---|
| Pubmed追加日 | 2025/1/25 |
|---|
| 投稿者 | Nie, Han; Zhao, Wenpeng; Wang, Qingqing; Zhou, Weimin |
|---|
| 組織名 | Department of Vascular Surgery, the Second Affiliated Hospital, Jiangxi Medical;College, Nanchang University, No. 1 Minde Road, Nanchang, Jiangxi 330006, China.;Jiangxi Provincial Institute of Traditional Chinese Medicine, No. 529 Wenjiao;Road, Nanchang, Jiangxi 330007, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39855644/ |
|---|
